Cargando…

IL-1 Inhibition in Systemic Juvenile Idiopathic Arthritis

Systemic juvenile idiopathic arthritis (sJIA) is the form of childhood arthritis whose treatment is most challenging. The demonstration of the prominent involvement of interleukin (IL)-1 in disease pathogenesis has provided the rationale for the treatment with biologic medications that antagonize th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giancane, Gabriella, Minoia, Francesca, Davì, Sergio, Bracciolini, Giulia, Consolaro, Alessandro, Ravelli, Angelo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2016
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5138234/ https://www.ncbi.nlm.nih.gov/pubmed/27999545 http://dx.doi.org/10.3389/fphar.2016.00467

Ejemplares similares

Juvenile Idiopathic Arthritis: Diagnosis and Treatment
por: Giancane, Gabriella, et al.
Publicado: (2016)

Clinical outcome measures in juvenile idiopathic arthritis
por: Consolaro, Alessandro, et al.
Publicado: (2016)

A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis
por: Bava, Cecilia, et al.
Publicado: (2019)

Agreement between objective and subjective definitions of inactive disease, remission and minimal disease activity in juvenile idiopathic arthritis
por: Schiappapietra, B, et al.
Publicado: (2011)

Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era
por: Giancane, Gabriella, et al.
Publicado: (2019)

PReS-FINAL-2132: Defining criteria for high disease activity in juvenile idiopathic arthritis: definition and validation of juvenile arthritis disease activity score cutoffs
por: Consolaro, A, et al.
Publicado: (2013)

PReS-FINAL-2143: Treat-to-target strategy in juvenile idiopathic arthritis: experience in 175 newly-diagnosed patients
por: Negro, G, et al.
Publicado: (2013)

PReS-FINAL-2176: Declines in levels of disease activity and physical disability in children with juvenile idiopathic arthritis seen in standard clinical care over the last 25 years
por: Consolaro, A, et al.
Publicado: (2013)

Drivers of non-zero physician global scores during periods of inactive disease in juvenile idiopathic arthritis
por: Alongi, Alessandra, et al.
Publicado: (2022)

A new approach to defining inactive disease, minimal disease activity and parent- and child-acceptable symptom state in juvenile idiopathic arthritis
por: Consolaro, A, et al.
Publicado: (2011)

Ferritin to Erythrocyte Sedimentation Rate Ratio: Simple Measure to Identify Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis
por: Eloseily, Esraa M. A., et al.
Publicado: (2019)

Is it worth allowing the presence of morning stiffness in the definition of inactive disease in juvenile idiopathic arthritis?
por: Allegra, Maddalena, et al.
Publicado: (2014)

Sensitivity and specificity of current diagnostic guidelines in children with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
por: Davì, Sergio, et al.
Publicado: (2011)

Sensitivity and specificity of current diagnostic guidelines in children with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
por: Davì, Sergio, et al.
Publicado: (2011)

Genetic determinants for methotrexate response in juvenile idiopathic arthritis
por: Pastore, Serena, et al.
Publicado: (2015)

Advanced bone age in the affected side predicts worse radiographic progression in patients with juvenile idiopathic arthritis and unilateral wrist disease
por: Varnier, Giulia Camilla, et al.
Publicado: (2014)

Comparison of the accuracy of different definitions of clinical remission (CR) and minimal disease activity (MDA) in juvenile idiopathic arthritis (JIA)
por: Davì, S, et al.
Publicado: (2008)

A controlled trial of intra-articular corticosteroids with or without methotrexate in oligoarticular juvenile idiopathic arthritis
por: Bracciolini, GP, et al.
Publicado: (2014)

The Influence of Overweight and Obesity on Treatment Response in Juvenile Idiopathic Arthritis
por: Giani, Teresa, et al.
Publicado: (2019)

Current Medical Treatments for Juvenile Idiopathic Arthritis
por: Ruperto, Nicolino, et al.
Publicado: (2011)

Juvenile Psoriatic Arthritis: Myth or Reality? An Unending Debate
por: Naddei, Roberta, et al.
Publicado: (2023)

Biomarkers of Response to Biologic Therapy in Juvenile Idiopathic Arthritis
por: Choida, Varvara, et al.
Publicado: (2021)

Comparison of physician's, parent's and patient's global ratings made on linear or 21-circle visual analogue scales (VAS) in juvenile idiopathic arthritis (JIA)
por: Dalprà, S, et al.
Publicado: (2008)

Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Still’s disease
por: Ruscitti, Piero, et al.
Publicado: (2022)

Development of new classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
por: Minoia, Francesca, et al.
Publicado: (2014)

PReS-FINAL-2345: Frequency of radiographic damage and progression in individual joints in children with juvenile idiopathic arthritis
por: Giancane, G, et al.
Publicado: (2013)

Update on the management of systemic juvenile idiopathic arthritis and role of IL-1 and IL-6 inhibition
por: Grevich, Sriharsha, et al.
Publicado: (2017)

Final validation of a new composite disease activity score for juvenile idiopathic arthritis: the Juvenile Arthritis Disease Activity Score (JADAS)
por: Consolaro, A, et al.
Publicado: (2008)

Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab
por: De Benedetti, Fabrizio, et al.
Publicado: (2014)

A three minute- screening tool for temporomandibular joint involvement in children with juvenile idiopathic arthritis
por: Giancane, Gabriella, et al.
Publicado: (2014)

Looking for the best strategy to treat children with new onset juvenile idiopathic arthritis: presentation of the “comparison of STep-up and step-down therapeutic strategies in childhood ARthritiS” (STARS) trial
por: Burrone, Marco, et al.
Publicado: (2022)

Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials
por: Malattia, Clara, et al.
Publicado: (2020)

PReS-FINAL-2164: Agreement among musculoskeletal pediatric specialists in the assessment of radiographic joint damage in juvenile idiopathic arthritis
por: Pignataro, R, et al.
Publicado: (2013)

Definition and Validation of the American College of Rheumatology 2021 Juvenile Arthritis Disease Activity Score Cutoffs for Disease Activity States in Juvenile Idiopathic Arthritis
por: Trincianti, Chiara, et al.
Publicado: (2021)

Analysis of ceiling effect and score distribution of outcome measures in juvenile idiopathic arthritis (JIA)
por: Lattanzi, B, et al.
Publicado: (2008)

Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis
por: Sota, Jurgen, et al.
Publicado: (2019)

Seeking insights into the EPidemiology, treatment and Outcome of Childhood Arthritis through a multinational collaborative effort: Introduction of the EPOCA study
por: Consolaro, Alessandro, et al.
Publicado: (2012)

Predictive Value of Magnetic Resonance Imaging in Patients With Juvenile Idiopathic Arthritis in Clinical Remission
por: Mazzoni, Marta, et al.
Publicado: (2022)

Proteomic profiling of extracellular vesicles in synovial fluid and plasma from Oligoarticular Juvenile Idiopathic Arthritis patients reveals novel immunopathogenic biomarkers
por: Raggi, Federica, et al.
Publicado: (2023)

Is it worth including subtalar joint in ultrasound ankle assessment of patients with juvenile idiopathic arthritis?
por: Lanni, Stefano, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_0sgbf7fpk3e6fu9p184ngk3o3b